GPR133 Activation Boosts Bone Strength in Mice, Hinting at Osteoporosis Therapies

A 2025 study from Leipzig and Shandong identifies the GPR133 (ADGRD1) receptor as crucial for bone density. Activating it with the chemical AP503 increases osteoblast activity and bone strength in mice, suggesting a potential therapy for osteoporosis that could work with exercise. While promising, these results are in animal models and require human testing; related 2024 work on a blood‑based regenerative implant and bone‑density hormones may inform future treatments.